Tuesday 12/9 Insider Buying Report: GMRE, PODD

Global Medical REIT CEO Mark Okey Decker Jr. disclosed a purchase of 10,000 GMRE shares at $32.51 each on Friday, a $325,100 buy that is roughly 7.3% in the money on today's high of $34.88 as the stock trades up about 5.4% on the day; Decker has bought GMRE three other times in the past year totaling $1.58 million at an average price of $7.87, indicating substantial insider accumulation. Separately, Insulet director Timothy C. Stonesifer purchased 962 shares at $311.73 each ($299,884 total) in his first filing in 12 months; Insulet is up about 0.7% on the day and recently traded as low as $297.63, roughly 4.5% below his purchase price.

Analysis

Global Medical REIT disclosed that CEO and President Mark Okey Decker Jr. purchased 10,000 shares on Friday at $32.51 per share for a $325,100 outlay; the stock hit a trading high of $34.88, putting Decker roughly 7.3% in the money, and GMRE was trading up about 5.4% on Tuesday. The size of the purchase and the immediate intraday price reaction indicate the market interpreted the trade as a positive signal for GMRE in the short term.

Decker’s filing also notes three prior purchases over the past year totaling $1.58 million at an average cost of $7.87 per share, reflecting substantial insider accumulation over time and a marked difference between historical and current acquisition prices. That history suggests a pattern of management buying that could reflect long-term conviction rather than a one-off tactical trade.

Separately, Insulet director Timothy C. Stonesifer bought 962 shares at $311.73 ($299,884), his first filing in 12 months; Insulet (PODD) was up about 0.7% on the day and traded as low as $297.63, roughly 4.5% below his purchase price. The article flags bargain-hunter interest in PODD at levels below Stonesifer’s buy, and both transactions are modestly bullish signals for investor sentiment but should be monitored alongside trading volume and subsequent filings.

Key Decisions for Investors

• Consider initiating or modestly increasing exposure to GMRE given CEO Mark Decker Jr.’s $325k purchase and prior $1.58m accumulation, but size position prudently and watch for confirming volume or additional filings
• For Insulet, consider waiting for a pullback toward the intraday low of $297.63 (about 4.5% below the director’s purchase) before adding exposure, or use a limit order around that level to improve entry price
• Monitor subsequent insider filings and intraday volume for both GMRE and PODD as confirmation signals; treat these insider buys as positive sentiment indicators rather than standalone fundamental validation